22:19 , Jun 19, 2019 |  BC Extra  |  Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

Catalent buys Italian facility from BMS  Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the...
16:59 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

APLN17 analog identified for abdominal aortic aneurysm

DISEASE CATEGORY: Cardiovascular INDICATION: Aneurysm An analog of APLN17 could help treat abdominal aortic aneurysm (AAA). Levels of APLN, which is processed into APLN17 and other APLN peptides, were higher in diseased aorta from AAA...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
00:12 , Jun 15, 2019 |  BC Extra  |  Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
20:51 , Jun 14, 2019 |  BC Extra  |  Politics & Policy

Amgen, Lilly, Merck sue HHS to block price disclosures in DTC ads

Three drug companies and the Association of National Advertisers have sued HHS in an attempt to block implementation of a CMS rule requiring list price disclosures in direct-to-consumer television advertisements. Amgen Inc. (NASDAQ:AMGN), Eli Lilly...
00:43 , Jun 11, 2019 |  BC Extra  |  Clinical News

Provention could use data from diabetes consortia to bring teplizumab to market faster

Results from a Phase II study showing Provention’s anti-CD3 mAb teplizumab delayed the onset of Type I diabetes in high-risk individuals raised the possibility of a faster path to market than the biotech’s Phase III...
00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
23:49 , Jun 6, 2019 |  BC Extra  |  Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
00:31 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Dual inhibition of CDK4 and CDK6 for pulmonary arterial hypertension

DISEASE CATEGORY: Cardiovascular INDICATION: Hypertension Patient sample and rat studies suggest dual inhibition of CDK4 and CDK6 could help treat pulmonary arterial hypertension (PAH). In lung samples from patients with idiopathic PAH, protein levels of...